ArticleCPT: pharmacometrics & systems pharmacology2026
Examining the Reliability of Model-Based Meta-Analysis (MBMA) Outcomes: A Simulation Study.
Article in CPT: pharmacometrics & systems pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Current State-of-the-Art and Future Advancements of Model-Based Meta-Analysis.CPT: pharmacometrics & systems pharmacology · 2026Article
- Examining the Reliability of Model-Based Meta-Analysis (MBMA) Outcomes: A Simulation Study.CPT: pharmacometrics & systems pharmacology · 2026Article
- Model-Based Meta-Analysis With MonolixSuite: A Tutorial for Longitudinal Categorical and Continuous Data.CPT: pharmacometrics & systems pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Model-based meta-analysis (MBMA) can be utilized to synthesize literature data and predict drug efficacy, particularly suitable for constructing external comparator arms for non-randomized controlled trials (NRCTs). This study evaluated the reliability of MBMA by comparing covariate models generated through MBMA to individual patient data. A pharmacodynamic covariate model, commonly employed in MBMA, was used to set true parameter values and simulate data across various scenarios. The reliability of MBMA models was assessed by comparing estimated to true parameter values and identifying optimal conditions for MBMA use. Linear and nonlinear covariate models were evaluated in 24 scenarios, focusing on the relative deviations of parameter estimates from their true values. Evaluation metrics included minimization successful rate, covariate introduction rate, and the accuracy of parameters such as E
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.